Heranba Industries Ltd

- Current borrowings of the company stand at around Rs. 300 crore (Rajkumar Bafna, CFO). - There is no explicit mention of any new fundraising plans through debt or equity in the transcript. - The company has ongoing CAPEX of approximately Rs. 50-100 crore planned to complete current projects (Raghuram K. Shetty). - Management indicates that after the ongoing CAPEX projects, no new major CAPEX or investments are expected in the near term. - No indication of raising fresh equity or significant additional debt was provided during the Q&A. - The company appears to be focusing on ramping up existing capacities and registrations rather than new fundraising. In summary, there is no disclosed plan for new debt or equity fundraising currently or imminently; the focus is on optimizing existing funds and ongoing CAPEX.

- Heranba has deployed approximately Rs. 425 crores in CAPEX over the last 2 years. - An additional Rs. 50 to 100 crores may be invested further to separate operations at two sites: Sarigam and Saykha. - Phase 1 commercial production at Sarigam facility started in Q2 FY25; Phase 2 expected by end of Q4 FY25. - Saykha facility (Greenfield) is expected to commence commercial production in Q4 FY25. - No new CAPEX projects are anticipated beyond ongoing expansions; existing capacities are being absorbed. - The new facilities will help diversify the product portfolio toward fungicides and herbicides. - The company is also planning an R&D setup at the Daikaffil unit to support internal and external development. - CAPEX is aimed at driving next-wave growth with 35% to 40% top-line growth expected in FY25-26.

- FY25 revenue target is Rs. 1,400 crore. - Two new production facilities (Sarigam phase II and Saykha) will start contributing from March end FY25, adding to next year's revenue. - Expected volume growth of around 3%-4% in Q3 and 9 months FY25. - Anticipated topline growth of 35%-40% in FY26 (2025-26), targeting revenue around Rs. 1,850 crores. - New facilities and expanded production capacity are expected to improve utilizations and drive growth. - Increased registrations in export markets (especially USA) expected to support growth in exports, though registration takes time. - Strong focus on new product launches in domestic and export markets, aiming for diversification into fungicides and herbicides beyond insecticides. - Overall, company expects steady ramp-up in realizations and sales volumes over FY25 and FY26.

- Heranba Industries targets a topline growth of 35% to 40% in FY25-26, driven by expanded production capacity and new product registrations. - EBITDA margins are expected to improve to the range of 12% to 14% in the next fiscal year, up from around 11% in the 9 months FY25. - Net profit margins are forecasted at around 5% to 6% in FY26, considering the improved EBITDA margins. - Volume growth is anticipated at around 3% to 4% for Q3 and 9 months FY25. - Ongoing CAPEX in Sarigam and Saykha facilities will contribute to increased turnover, targeting revenues around Rs. 1850 crores in FY25-26. - Registrations in export markets like the US are expected to boost export growth in coming years. - FY25 is considered a transition year with expectations of better earnings and profitability from FY26 onwards.

The transcript does not explicitly mention the current or expected order book or pending orders for Heranba Industries Limited. However, from the discussion, some relevant points can be inferred: - The company is seeing a preparation for the next quarter which is mostly B2B. - Registration activities are ongoing, especially for new products aimed at the Indian market and export markets. - Export sales have been affected due to inventory issues and slower demand but are expected to improve with new registrations. - Demand and pricing are expected to improve in the upcoming quarters, indicating potential for increased order intake. - The ramp-up of new production facilities and expanded capacities indicate expected higher future order volumes. - Growth guidance for FY25-26 is 35% to 40% in topline, suggesting a strong order pipeline. No specific quantitative details on order book or pending orders are provided.